Loading
PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more.
Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection. Binds specifically to the PRDI element in the promoter of the beta-interferon gene.
CIViC holds 2 clinical evidence items and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.96, genetic association 0.10, somatic mutation 0.88). IntOGen calls it a driver in 7 cohorts (3 activating, 4 loss-of-function), covering Acute Myeloid Leukaemia, Diffuse Large B-Cell Lymphoma, NOS, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prostate.
In plain words · PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more.
PRDM1 (PR domain zinc finger protein 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma, Multiple myeloma, Prostate cancer and 5 more.
Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs.
No product in this corpus aims at PRDM1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA PRDM1: RNA tissue enhanced (esophagus 52 nTPM); blood lineage group enriched (granulocytes 13 nTPM, T-cells 34 nTPM); high antibody staining in 11 normal tissues; highest cancer staining carcinoid (1 of 4 high). Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lymphoma, Multiple myeloma, Prostate cancer, Skin cancer (all types), Colorectal cancer, Ovarian cancer, Leukaemia); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O75626; CIViC gene PRDM1; IntOGen PRDM1; Human Protein Atlas PRDM1 tissue; Open Targets ENSG00000057657 associations
First described 1991. Earliest sequence paper UniProt cites for the protein: Keller A.D. et al, Genes Dev, 1991, "Identification and characterization of a novel repressor of beta-interferon gene expression". Source.
Sources: HGNC HGNC:9346 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75626 (protein name, function text, keywords and locations (REST API)); CIViC gene PRDM1 (2 evidence items, 0 assertions, 1 variants; diseases: Diffuse Large B-cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000057657 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: colorectal cancer 0.52, ovarian cancer 0.50, melanoma 0.55, diffuse large B-cell lymphoma 0.59, non-Hodgkin lymphoma 0.62, skin cancer 0.56 (GraphQL API, CC0)); IntOGen PRDM1 (driver in 7 cohorts (Act 3, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcription factor that mediates a transcriptional program in various innate and adaptive immune tissue-resident lymphocyte T cell types such as tissue-resident memory T (Trm), natural killer (trNK) and natural killer T (NKT) cells and negatively regulates gene expression of proteins that promote the egress of tissue-resident T-cell populations from non-lymphoid organs. Plays a role in the development, retention and long-term establishment of adaptive and innate tissue-resident lymphocyte T cell types in non-lymphoid organs, such as the skin and gut, but also in other nonbarrier tissues like liver and kidney, and therefore may provide immediate immunological protection against reactivating infections or viral reinfection. Binds specifically to the PRDI element in the promoter of the beta-interferon gene. Drives the maturation of B-lymphocytes into Ig secreting cells. Associates with the transcriptional repressor ZNF683 to chromatin at gene promoter regions. Binds to the promoter and acts as a transcriptional repressor of IRF8, thereby promotes transcription of osteoclast differentiation factors such as NFATC1 and EEIG1. Location: Nucleus; Cytoplasm (UniProt). Locus 6q21 (HGNC).
RNA: tissue enhanced (esophagus 52 nTPM), detected in all normal tissues. Blood: group enriched (granulocytes 13 nTPM, T-cells 34 nTPM).
Medium: Breast, Bronchus, Cerebral cortex, Colon, Duodenum, Endometrium, Epididymis, Fallopian tube.
Medium only: breast cancer, colorectal cancer, endometrial cancer, glioma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PRDM1" OR ABSTRACT:"PRDM1" OR TITLE:"PR/SET domain 1" OR ABSTRACT:"PR/SET domain 1" OR TITLE:"PR domain zinc finger protein 1" OR ABSTRACT:"PR domain zinc finger protein 1" OR TITLE:"PRDI-BF1" OR ABSTRACT:"PRDI-BF1" OR TITLE:"Blimp-1" OR ABSTRACT:"Blimp-1" OR TITLE:"BLIMP1" OR ABSTRACT:"BLIMP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PRDM1, not a curated reading list.